Debra Travers is President and CEO of PolyAurum LLC. She comes to PolyAurum after a 30+ year career as an accomplished strategic healthcare executive and entrepreneur with diverse and progressive product development and commercialization experience in global pharmaceutical and biomedical companies, including Centocor, GSK, Endo Pharmaceuticals and IMS Health. She has extensive experience in commercial assessment, technical development, registration, launch and life cycle management for life sciences products and services.
Dr. David Cormode, DPhil, Founder and Scientific Advisor, is Assistant Professor in the Department of Radiology at the Perelman School of Medicine at the University of Pennsylvania. He has over 10 years of experience in the development of novel metal nanoparticles. He has published over 60 papers, primarily on the topic of nanoparticle contrast agents.
Dr. Rabe’e Cheheltani, PhD, Founder and Scientific Advisor, was a postdoctoral fellow in the Dr. Cormodes’s lab in the Department of Radiology at the Perelman School of Medicine at the University of Pennsylvania. Her research focused on nanoparticles as contrast agents in medical imaging. Dr. Cheheltani currently works as a consultant for IQVIA.
Dr. Jay Dorsey, MD, PhD, Founder and Scientific Advisor, is Assistant Professor of Radiation Oncology (tenure track) at the Perelman School of Medicine at the University of Pennsylvania. He is a board-certified Radiation Oncologist with expertise in CNS cancers and radiosurgery. He is PI of a translational research laboratory focused on theranostic agent development and tumor biomarkers.
Dr. Andrew Tsourkas, PhD, Founder and Scientific Advisor, is a Professor of Bioengineering and is the Associate Director for the Center for Targeted Therapeutics and Translational Nanomedicine at the University of Pennsylvania. He has 15 years of experience in the development of nanoparticles for both therapeutic and imaging applications.
Jason Summa, Director, Clinical Project Scientist, Oncology at Janssen, a division of Johnson and Johnson is advising PolyAurum as part of the JLABS accelerator program. He has 15 years of hands-on experience in clinical science, operations and regulatory affairs in both small biotech and large pharmaceutical companies with a results-proven track record in developing novel products. Before J&J, Jason led clinical development efforts at BIND Therapeutics in the pursuit of developing and evaluating polymeric nanoparticles for oncology.